Pyruvate kinase activators for use in therapy
Described herein are methods for using compounds that activate pyruvate kinase.
1. A method for treating sickle cell anemia in a subject comprising administering to the subject a therapeutically effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the compound is:
2. A method for treating thalassemia in a subject comprising administering to the subject a therapeutically effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the compound is:
3. The method of claim 2 wherein the thalassemia is beta-thalassemia.
4. A method for increasing the lifetime of red blood cells (RBCs) in need thereof comprising contacting blood with a therapeutically effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the compound is:
5. The method of claim 4 wherein the compound, pharmaceutically acceptable salt thereof or pharmaceutically acceptable composition is administered to a subject in need thereof.
6. The method of claim 4 wherein the compound, pharmaceutically acceptable salt thereof or pharmaceutically acceptable composition is added directly to whole blood or packed red blood cells extracorporeally.
7. A method for regulating the levels of 2,3-diphosphoglycerate (2,3-DPG) levels in blood in need thereof comprising contacting blood with an effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the compound is:
8. The method of claim 7 wherein the compound, pharmaceutically acceptable salt thereof or pharmaceutically acceptable composition is administered to a subject in need thereof.
9. The method of claim 7 wherein the compound, pharmaceutically acceptable salt thereof or pharmaceutically acceptable composition is added directly to whole blood or packed red blood cells extracorporeally.
10. A method for treating hemolytic anemia in a subject comprising administering to the subject a therapeutically effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the hemolytic anemia is selected from congenital anemia and hereditary spherocytosis and wherein the compound is:
11. The method of claim 10 wherein the hemolytic anemia is congenital anemia.
12. The method of claim 10 wherein the hemolytic anemia is hereditary spherocytosis.